Evogene Ltd. (EVGN) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals declining revenues, increased costs, and significant operating and net losses, indicating financial struggles. Despite cost reductions, the lack of clear guidance and vague responses during the Q&A, particularly regarding financial terms and timelines, adds uncertainty. The promising strategic shifts and partnerships, including with Google, are overshadowed by the immediate financial challenges. The market is likely to react negatively in the short term due to these concerns, leading to a predicted stock price movement in the negative range of -2% to -8%.
Key Financial Performance
Operating Expenses (Annual) $13.8 million for 2025, down from $22 million in 2024, a decrease of $8.2 million. This was due to organizational realignment and cost reduction initiatives.
Operating Expenses (Q4) $3.2 million in Q4 2025, down from $4.3 million in Q4 2024, a decrease of $1.1 million. This reflects the effects of cost reduction measures.
Revenues (Annual) $3.9 million for 2025, down from $5.6 million in 2024, a decrease of $1.7 million. The decline was primarily due to lower revenue from AgPlenus' activity and the completion of a collaboration agreement with Corteva in 2024.
Revenues (Q4) $0.3 million in Q4 2025, down from $1.5 million in Q4 2024, a decrease of $1.2 million. This was mainly due to reduced seed sales by Casterra.
Cost of Revenues (Annual) $4.1 million for 2025, up from $2.4 million in 2024, an increase of $1.7 million. This was primarily due to a $2.2 million inventory impairment recorded by Casterra.
Cost of Revenues (Q4) $2.3 million in Q4 2025, up from $0.7 million in Q4 2024, an increase of $1.6 million. This was mainly driven by the inventory impairment of Casterra.
R&D Expenses (Annual) $8 million for 2025, down from $12.5 million in 2024, a decrease of $4.5 million. The reduction was due to decreased R&D expenses in Biomica, Casterra, and AgPlenus.
R&D Expenses (Q4) $1.8 million in Q4 2025, down from $2.7 million in Q4 2024, a decrease of $0.9 million. This was mainly attributed to decreased expenses in Biomica.
Sales and Marketing Expenses (Annual) $1.5 million for 2025, down from $2 million in 2024, a decrease of $0.5 million. The reduction was mainly due to lower personnel costs in Evogene and Biomica.
Sales and Marketing Expenses (Q4) $0.3 million in Q4 2025, down from $0.4 million in Q4 2024, a decrease of $0.1 million. This was due to reductions in personnel costs.
General and Administrative Expenses (Annual) $4.3 million for 2025, down from $7 million in 2024, a decrease of $2.7 million. This was mainly due to a provision for doubtful debt and transaction costs recorded in 2024, as well as reduced activity and personnel costs in Biomica.
General and Administrative Expenses (Q4) $0.9 million in Q4 2025, down from $1.3 million in Q4 2024, a decrease of $0.4 million. This was primarily due to decreased expenses in Evogene and Biomica.
Operating Loss (Annual) $14 million for 2025, down from $18.8 million in 2024, a decrease of $4.8 million. This was due to decreased operating expenses, partially offset by reduced revenues and higher cost of revenues.
Operating Loss (Q4) $5.2 million in Q4 2025, up from $3.5 million in Q4 2024, an increase of $1.7 million. This was due to decreased revenues and increased cost of revenues, partially offset by decreased operating expenses.
Net Loss (Annual) $7.8 million for 2025, down from $18.1 million in 2024, a decrease of $10.3 million. This was due to decreased operating expenses and income from discontinued operations, partially offset by reduced revenues, higher cost of revenues, and decreased financing income.
Net Loss (Q4) $5.4 million in Q4 2025, up from $5,000 in Q4 2024, an increase of $5.395 million. This was due to decreased financial income, decreased revenues, and increased cost of revenues, partially offset by decreased operating expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ChemPass AI: Focused on designing novel, highly potent small molecules for drug development and ag chemicals. It generates molecules based on vast chemical territories and optimizes them for multiple parameters to increase development success.
Google Cloud Collaboration: Completed first collaboration in mid-2025, achieving 90% design precision. Initiated a second collaboration in February 2026 to integrate advanced AI agents for improved discovery and scaling capabilities.
Human Health: Advancing multiple partnered drug discovery programs with biotechnology companies and academic institutions. Four collaborations disclosed, with plans to scale further.
Agriculture: Subsidiary AgPlenus is developing novel herbicides and fungicides using ChemPass AI. Collaborations with Bayer and Corteva are ongoing, with plans for expansion.
Cost Reduction: Operating expenses reduced to $13.8 million in 2025 from $22 million in 2024. Fourth quarter expenses decreased to $3.2 million from $4.3 million in 2024.
Subsidiary Restructuring: Lavie Bio sold majority of operations to ICL, reducing expenses. Biomica scaled down operations and entered a license agreement for its oncology candidate. AgPlenus integrated into core operations, and Casterra ceased operations in Kenya to focus on Brazil.
Strategic Focus: Shifted focus to ChemPass AI and streamlined business activities to concentrate on human health and agriculture markets.
Partnership Model: Adopted a partnership-driven workflow for small molecule discovery and optimization, aiming to become a preferred partner in pharma and agriculture industries.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Geopolitical Instability: The aftermath of the recent war between Israel and terrorist groups, including Hamas and Hezbollah, as well as regional destabilizations in the Middle East, poses risks to the company's operations and overall stability.
Revenue Decline: Revenues for 2025 decreased by $1.7 million compared to 2024, primarily due to lower revenue from AgPlenus' activities and reduced seed sales by Casterra.
Inventory Impairment: Casterra recorded an inventory impairment of approximately $2.2 million due to ceasing operations in Kenya, which negatively impacted cost of sales.
Market Demand Challenges: Casterra faced a significant decline in demand for castor seeds, leading to operational downsizing and market focus shift to Brazil.
Operational Streamlining Risks: The company implemented organizational realignments, cost reductions, and divestments, which could pose risks to operational efficiency and strategic execution.
Decreased R&D Investments: R&D expenses decreased significantly, which may impact the company's ability to innovate and maintain competitive advantage in the long term.
Reduced Financial Income: Financing income net for 2025 dropped significantly compared to 2024, primarily due to changes in accounting treatment of warrants, impacting overall financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Future Collaborations and Partnerships: Evogene plans to scale its activities with additional collaborations in human health and agriculture. The company expects to expand its partnerships with biotechnology companies, academic institutions, and multinational agriculture companies, including Bayer and Corteva.
ChemPass AI Development: Evogene is integrating advanced AI agents into ChemPass AI using Google Cloud Vertex AI to decrease manual errors and automate complex workflows. This aims to improve the probability of development success for novel small molecule candidates.
Agriculture Market Focus: The company anticipates continued growth in agriculture through the expansion of collaborations and the formation of new partnerships. AgPlenus, a subsidiary, is focused on developing novel herbicides and fungicides.
Human Health Market Focus: Evogene aims to advance multiple partnered drug discovery programs and expects to present similar advancements during the remainder of 2026 and beyond.
Cost Reduction and Organizational Realignment: The company expects the reduced expense level achieved in 2025 to be sustained in future periods. Subsidiaries like Lavie Bio and Biomica anticipate distributing the majority of their remaining cash to shareholders, including Evogene, during 2026.
Long-term Strategic Goals: Evogene aims to develop its own product pipeline in the long term, leveraging its proprietary technology for competitive advantage.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you speak to the terms of the BMC128 license agreement with Lishan Pharmaceuticals?
A:The agreement with Lishan includes milestone payments based on advancing BMC128 in the pipeline or any commercial transaction generating value for Lishan. Additionally, there will be revenue sharing from the end product's revenue. The numbers in pharma could be significant, benefiting both Biomica and Evogene as a major shareholder in Biomica.
Q:Can you speak to the magnitude of cash potentially coming in from Lavie Bio and Biomica?
A:The cash from the acquisition of Lavie Bio and MicroBoost by ICL is expected to satisfy Evogene's needs for at least mid-next year, possibly more. Current operations have sufficient cash for more than 1.5 years even without additional financial transactions.
Q:Can you highlight investor catalysts over the coming 12 months?
A:Three types of catalysts were highlighted: 1) Technology collaborations with companies like Google and others, leveraging their assets and knowledge. 2) Collaboration agreements with midsized biotech and pharma companies using ChemPass AI to identify small molecules. 3) Collaboration agreements with chemical companies, with a focus on innovation and leveraging AgPlenus' performance. These catalysts are expected to drive strategic growth for Evogene.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details about the financial terms of the BMC128 license agreement with Lishan Pharmaceuticals, using vague language like 'significant' without numerical evidence. Additionally, while discussing investor catalysts, the response lacked clarity on specific companies or timelines, and avoided addressing other activities like Casterra and legacy operations.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI engine
Biomica
Cost revenue
Iran
Ltd
Ofer
Series warrant
activity market
activity personnel
advantage
ag chemical
agent
candidate partner
capability molecule
capital allocation
choice
cost revenue
development ag
development success
differentiation
exercise
expense level
generation
group
income net
inventory impairment
majority cash
net period
objective
outset
parameter
placement
probability
product candidate
requirement
revenue cost
revenue inventory
transformation
workflow
world
EVGN Transcript
Evogene Ltd. (EVGN) Q4 2025 Earnings Call Transcript
Unknown3-5
The earnings call reveals declining revenues, increased costs, and significant operating and net losses, indicating financial struggles. Despite cost reductions, the lack of clear guidance and vague responses during the Q&A, particularly regarding financial terms and timelines, adds uncertainty. The promising strategic shifts and partnerships, including with Google, are overshadowed by the immediate financial challenges. The market is likely to react negatively in the short term due to these concerns, leading to a predicted stock price movement in the negative range of -2% to -8%.
Evogene Ltd. (EVGN) Q3 2025 Earnings Call Transcript
Positive11-20
The earnings call reveals a mixed but overall positive sentiment. Financial performance shows improvement in net loss and operating loss, though revenues slightly decreased. The AI ChemPass platform is gaining interest, with potential partnerships on the horizon. Management's enthusiasm for AI ChemPass and planned IR activities could boost investor confidence. Despite some unclear responses in the Q&A, the focus on strategic partnerships and financial health supports a positive outlook for stock price movement.
Evogene Ltd. (EVGN) Q2 2025 Earnings Call Transcript
Positive8-19
The earnings call highlights strong revenue growth, significant reductions in operating expenses, and promising developments in castor seed sales and field trials. The Q&A section reveals optimism about future collaborations and advancements, particularly in the ChemPass AI platform. Despite some vague responses, the focus on new strategies and partnerships suggests a positive outlook. The financial improvements and strategic plans indicate a likely stock price increase of 2% to 8% over the next two weeks.
Evogene Ltd. (NASDAQ:EVGN) Q1 2025 Earnings Call Transcript
Unknown5-22
The earnings call presents a mixed picture. While there are positive developments, such as the acquisition of Lavie Bio by ICL and reduced expenses, there are concerns over declining revenues, operational risks, and funding challenges. The Q&A session highlights management's reluctance to provide clear guidance, raising uncertainties. Despite reduced expenses and a cash inflow from asset sales, the reliance on subsidiaries for revenue and the lack of clarity on future orders temper optimism. Given these factors, the stock price is likely to remain stable, resulting in a neutral sentiment.
EVGN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
